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Abstract
Bovine	xenograft	materials,	followed	by	synthetic	biomaterials,	which	unfortunately	
still	 lack	documented	predictability	and	clinical	performance,	dominate	the	market	
for	the	cranio-	maxillofacial	area.	In	Europe,	new	stringent	regulations	are	expected	
to	further	limit	the	allograft	market	in	the	future.
Aim: Within	this	narrative	review,	we	discuss	possible	future	biomaterials	for	bone	
replacement.
Scientific Rationale for Study: Although	the	bone	graft	(BG)	literature	is	overflooded,	
only	a	handful	of	new	BG	substitutes	are	clinically	available.	Laboratory	studies	tend	
to	focus	on	advanced	production	methods	and	novel	biomaterial	features,	which	can	
be	costly	to	produce.
Practical Implications: In	this	review,	we	ask	why	such	a	limited	number	of	BGs	are	
clinically	available	when	compared	to	extensive	laboratory	studies.	We	also	discuss	
what	features	are	needed	for	an	ideal	BG.
Results: We	have	identified	the	key	properties	of	current	bone	substitutes	and	have	
provided	important	information	to	guide	clinical	decision-	making	and	generate	new	
perspectives	 on	 bone	 substitutes.	Our	 results	 indicated	 that	 different	mechanical	
and	 biological	 properties	 are	 needed	 despite	 each	 having	 a	 broad	 spectrum	 of	
variations.
Conclusions: We	foresee	bone	replacement	composite	materials	with	higher	levels	of	
bioactivity,	 providing	 an	 appropriate	 balance	 between	 bioabsorption	 and	 volume	
maintenance	for	achieving	ideal	bone	remodelling.
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1  | INTRODUC TION
Bone	defects	resulting	from	trauma,	disease,	surgery	or	congen-
ital	 malformations	 are	 a	 significant	 health	 problem	 worldwide.	
Bone	is,	indeed,	the	second	most	transplanted	tissue	after	blood.	
Several	countries	are	currently	experiencing	an	exceedingly	high	
demand	for	bone	grafts	 (BGs)	and	bone	tissue	engineering	solu-
tions.	In	the	United	States	and	Europe,	more	than	half	a	million	pa-
tients	annually	receive	bone	defect	repairs	with	a	cost	estimated	
to	be	greater	than	US$3	billion	(Amini,	Laurencin,	&	Nukavarapu,	
2012;	MarketReport,	 2017).	 This	 number	 is	 expected	 to	 double	
globally	by	2020	due	to	a	variety	of	factors,	such	as	the	growing	
needs	of	the	world	population,	increased	life	expectancy	(Baroli,	
2009)	and	increased	access	to	advanced	health	services	and	assis-
tance,	particularly	in	growing	countries.	The	European	market	for	
dental	BGs	has	shown	improvements	in	growth	due	to	several	fac-
tors	and	trends.	A	major	contributor	of	this	growth	has	been	the	
healthy	 expansion	 of	 the	 European	 dental	 implant	 market,	 par-
ticularly	in	regions	where	implant	penetration	has	been	relatively	
low	 (e.g.	 France	and	 the	United	Kingdom)	 and	 in	 those	where	 it	
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kept	growing	significantly	(e.g.	Italy	and	Germany,	MarketReport,	
2015).
The	 current	 gold	 standard	 for	 bone	 defect	 repair	 is	 still	 au-
tologous	 (i.e.	 sourcing	 the	 bone	 from	 the	 patients	 themselves)	
(Giannoudis,	Chris	Arts,	Schmidmaier,	&	Larsson,	2011;	De	Grado	
et	al.,	 2018).	 These	 grafts	 are,	 self-	evidently,	 histocompatible	
and	non-	immunogenic	 and	offer	 all	 of	 the	 imperative	properties	
required	 for	 a	 BG.	 Specifically,	 autografts	 possess	 the	 essential	
components	 to	 achieve	 osteoinduction,	 osteogenesis	 and	 os-
teoconduction	 (Amini	 et	al.,	 2012).	 However,	 autografts	 require	
a	 secondary	 surgical	procedure	at	 the	 site	of	 the	 tissue	harvest,	
which	can	lead	to	complications	such	as	donor	site	injury,	morbid-
ity,	 deformity	 and	 scarring.	 In	 addition,	 harvesting	 and	 implant-
ing	 autografts	 is	 an	 expensive	 procedure	 that	 is	 also	 associated	
with	high	surgical	risks,	such	as	bleeding,	inflammation,	infection,	
chronic	pain	and	higher	costs.	Furthermore,	autografts	may	not	be	
a	 treatment	option	when	 the	defect	 site	 requires	 large	 amounts	
of	 bone	 (Ebraheim,	 Elgafy,	 &	 Xu,	 2001;	 St	 John	 et	al.,	 2003).	 In	
the	cranio-	maxillofacial	area,	autografts	play	a	marginal	role,	being	
widely	overtaken	by	allografts	in	the	United	States	and	by	bovine	
xenografts	 in	 Europe	 for	 reasons	 related	 to	 costs/benefits	 (Jo,	
S.H.	et	al.,	2018).
Although	 BGs	 have	 been	 used	 for	 decades	 to	 improve	 bone	
repairs,	 none	 of	 the	 currently	 available	 BGs	 possess	 all	 the	 de-
sirable	 characteristics	 that	 such	 a	 biomaterial	 should	 have:	 high	
osteoinductive	 and	 angiogenic	 potentials,	 biological	 safety,	 low	
patient	morbidity,	high	volumetric	stability,	easy	market	availabil-
ity,	 long	shelf	 life	and	 reasonable	production	costs	 (Bose,	Roy,	&	
Bandyopadhyay,	 2012;	 Hutmacher,	 2006;	 El-	Rashidy,	 Roether,	
Harhaus,	 Kneser,	 &	 Boccaccini,	 2017).	 The	 problems	 associated	
with	 transplanted	 grafts	 have	 raised	 interest	 in	 synthetically	 im-
proved	 BGs	 (Board,	 2018;	 Rothermundt	 et	al.,	 2014).	 This	 can	
be	 seen	 also	 by	 the	 increasing	 number	 of	 publications	 on	 BGs.	
Thompson's	 Web	 of	 Science®	 shows	 an	 almost	 triplicate	 in	 the	
number	of	publications	using	the	search	terms	“bone	graft	substi-
tute”,	“bone	scaffold”	and	“bone	graft”	for	the	period	of	1997–2017	
(Figure	1),	with	more	than	6,000	papers	published	 in	 this	 field	 in	
2017	alone.	The	mismatch	between	the	extraordinarily	high	num-
ber	of	laboratory	studies	on	new	BGs	and	the	low	number	of	clinical	
studies	is	apparent.	From	the	myriad	of	solutions	suggested	by	an	
abundant	literature	(Figure	1),	new	BGs	that	are	certified	as	med-
ical	devices	and	hence	made	available	for	the	cranio-	maxillofacial	
market	are	limited.	One	reason	for	this	gap	is	the	cost	margin	for	
BGs	 in	 cranio-	maxillofacial	 applications,	 which	 limit	 the	 market	
to	 BGs	 with	 complex	 and	 costly	 production	 processes.	 Another	
reason	 is	 the	 relatively	 low	number	of	 clinical	 studies	 comparing	
BGs;	some	in	vivo	studies	compare	different	BGs	(Araujo,	Linder,	
&	Lindhe,	2009;	Santos	et	al.,	2010;	Benic	et	al.,	2017;	Jung	et	al.,	
2017;	Lambert	et	al.,	2017).	Consequently,	only	a	 few	BGs	today	
dominate	the	cranio-	maxillofacial	market.	Nonetheless,	there	is	an	
increasing	demand	for	a	new	generation	of	synthetic	BGs	with	a	
higher	degree	of	 bioactivity	 and	mechanical	 strength	 and	manu-
factured	with	cost-	efficient	methods.
2  | RE VIE W OF CURRENT LITER ATURE
2.1 | Literature search
This	 narrative	 review	 follows	 the	 guidelines	 in	 PRISMA's	 state-
ment	 (http://www.prisma-statement.org/).	 We	 performed	 our	
search	 on	 MEDLINE	 (through	 the	 PubMed	 interface),	 Google	
Scholar	and	Web	of	Science.	We	created	an	ad	hoc	search	string	
combining	keywords	with	the	use	of	Boolean	operators	“AND”	and	
“OR”.	The	search	string	was	as	follows:	([“bone	graft	material”	OR	
“bone	 graft	 substitute”]	 AND	 [“bone	 scaffold”	OR	 “bone	 forma-
tion”	OR	“regeneration”	OR	“ideal”).	Limits	were	set	to	the	English	
language	and	the	year	of	publication	2000–2018.	Additionally,	we	
searched	records	for	“commercial	drivers”	AND	“market	limitation”	
AND	“bone	graft	substitute”	AND/OR	“bone	scaffolds”.	Although	
the	focus	area	for	this	review	is	the	cranio-	maxillofacial	field,	stud-
ies	from	the	orthopaedic	field	have	been	included	to	provide	more	
evidence	between	BG	and	its	interaction	with	the	bone.	Regarding	
the	 data	 collection,	 two	 reviewers	 (HJH,	 GP)	 independently	
screened	the	titles	and	the	abstracts	of	the	initially	retrieved	arti-
cles	and	other	records.	Abstracts	and	records	that	were	not	avail-
able	or	did	not	provide	sufficient	information	were	excluded.	HJH	
and	GP	 resolved	all	 disagreements	 through	discussion.	To	verify	
inclusion	 criteria	 independently,	 the	 two	 reviewers	 assessed	 the	
full	 texts	 of	 all	 studies	 of	 possible	 relevance.	 Exclusion	 criteria	
were	as	follows:	studies	presenting	incomplete	data	(e.g. mean val-
ues	without	 standard	 deviations)	 and	 quantitative	 analyses	with	
less	 than	 eight	 total	 specimens.	 The	 researchers	 recorded	 their	
reasons	for	exclusion	at	this	stage.	See	the	flow	chart	to	examine	
the	record-	selection	process	(Figure	2).
2.2 | Properties of an ideal bone graft 
substitute material
BGs	are	used	to	repair	and	rebuild	diseased	bones	in	a	human	body	
that	 is	 unable	 to	 heal	 the	 bone	 by	 itself.	 To	 perform	 this	 kind	 of	
repair,	 a	 porous	 structure	 that	 is	 capable	 of	 supporting	 new	 and	
healthy	 three-	dimensional	 tissue	 formation	 is	 essential	 (Huiskes,	
Ruimerman,	van	Lenthe,	&	Janssen,	2000).	Attempts	to	define	the	
ideal	BG	has	 already	been	 attempted	30	years	 ago	 (Lemons	 et	al.,	
1988).	Despite	extensive	research	in	the	past	30	years	(Figure	1),	a	
BG	that	meets	all	these	requirements	has	yet	to	be	developed;	yet,	
we	 still	 continue	 to	 redefine	 the	 BG's	 desirable	 properties.	 A	 BG	
should	meet	specific	 requirements	to	achieve	 its	goal.	First,	an	 in-
terconnected	porosity	with	an	adequate	pore	size	should	allow	for	
diffusion	throughout	the	whole	BG	for	bone	cells,	nutrients	and	ex-
change	of	waste	products.	 The	very	minimum	pore	 size	 is	 around	
100 μm;	however,	pore	sizes	>300	μm	are	recommended	for	allow-
ing	vascularization	and	new	bone	formation	(Karageorgiou	&	Kaplan,	
2005;	Murphy,	Haugh,	&	O'Brien,	2010;	Saito	et	al.,	2012).	The	sec-
ond	requirement	is	a	surface	that	allows	vascular	ingrowth,	bone	cell	
attachment,	migration	and	proliferation.	The	third	is	adequate	me-
chanical	compressive	strength	and	elasticity	for	allowing	absorbance	
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of	the	load	from	surrounding	hard	and	soft	tissues	in	non-	contained	
defects.	 The	 fourth	 is	 controlled	 biodegradability,	 which	 ensures	
resorption	during	the	tissue-	remodelling	process	while	maintaining	
defect	volume	for	bone	ingrowth.	The	last	requirement	is	sufficient	
dimensional	stability	for	allowing	the	chairside	adaptation	of	the	BG	
to	the	defect.
The	 BG	 can	 be	 divided	 according	 to	 several	 categorizations	
(Planell,	Best,	Lacroix,	&	Merolli,	2009);	here,	we	chose	to	divide	be-
tween	biological	 and	 synthetic	 biomaterials.	 The	main	 advantages	
and	disadvantages	are	 listed	 in	Table	1.	 Independently	of	 the	BGs’	
chemical	compositions,	other	parameters,	such	as	surface	morphol-
ogy	 and	 internal	 pore	 architecture	 like	 pore	 size,	 porosity,	 inter-
connectivity	and	pore	structure,	control	 for	 their	osteoconductive	
properties	(Kasten	et	al.,	2008;	von	Doernberg	et	al.,	2006).	Another	
important	 condition	 is	 the	 resorbability	 of	 the	materials.	 An	 ideal	
BG	substitute	 is	expected	 to	be	 replaced	by	bone	and	remodelled	
at	a	tailored	absorption	rate	(Williams,	2008;	Murphy	et	al.,	2010).	
Ideally,	 cells	 such	 as	 osteoclasts	 and	 macrophages	 should	 resorb	
or	 dissolve	 synthetic	 BG	 substitutes	 (Schmidt-	Rohlfing,	 Tzioupis,	
Menzel,	&	Pape,	2009),	while	materials	like	polymers	are	degraded	
mainly	hydrolytically	or	enzymatically.	The	chemical	stability	of	syn-
thetic	biomaterials	often	 impedes	these	mechanisms	 (Planell	et	al.,	
2009;	Corbella,	Taschieri,	Weinstein,	&	Del	Fabbro,	2016;	Ceccarelli	
et	al.,	2017).
2.3 | Allografts
Allografts,	which	can	include	tissue	from	both	living	human	donors	
and	 cadavers,	 represent	 the	 second	 most	 common	 bone-	grafting	
technique	worldwide	(Amini	et	al.,	2012).	An	allogenic	BG	refers	to	
bony	tissue	that	is	harvested	from	one	individual	and	transplanted	
to	a	genetically	different	individual	of	the	same	species	(Roberts	&	
Rosenbaum,	2012;	Goldberg	&	Akhavan,	2005).	Allografts	are	also	
similarly	 histocompatible	 and	 available	 in	 various	 forms,	 including	
demineralized	 bone	 matrices,	 cancellous	 chips,	 cortico-	cancellous	
and	 cortical	 grafts	 and	 osteochondral	 and	 whole-	bone	 segments,	
depending	on	 the	host	 site's	 requirements	 (Finkemeier,	 2002a).	 In	
comparison	with	autografts,	 allografts	are	associated	with	 risks	of	
immunoreactions	and	transmission	of	infections	and	have	numerous	
proven	records	of	high	failure	rates	over	 long-	term	use	 (De	Grado	
et	al.,	2018;	Winkler,	Sass,	Duda,	&	Schmidt-	Bleek,	2018).	Allografts	
are	 devitalized	 (and	 often	 sterilized)	 mainly	 through	 decalcifica-
tion,	 deproteinization,	 irradiation	 and/or	 freeze-	drying	 processing;	
they	 therefore	 lack	cells	and	have	 reduced	osteoinductive	proper-
ties	(Wheeler	&	Enneking,	2005;	Delloye,	Cornu,	Druez,	&	Barbier,	
2007).	Finally,	 as	well	 as	 importantly,	 there	 is	 an	 increasing	 short-
age	of	supplies	in	tissue	donations	each	year.	For	all	these	reasons	
and	due	 to	 increased	regulatory	 restrictions	particularly	 in	Europe	
(European	Tissue	and	Cells	Directive;	EUTCD,	2004)	 and	 the	new	
medical	 device	 regulation	 (MDR,	 2017),	 allografts	 are	 frequently	
abandoned	in	clinical	practice.	These	factors	are	significant	market	
restraints	 for	manufacturers	 and	 hinder	 the	 rapid	 shift	 from	 allo-
grafts	to	other	BG	substitutes	(MarketReport,	2017).
2.4 | Xenografts
Xenografts	 involve	 the	 transplantation	 of	 bone	 tissue	 across	 spe-
cies.	The	use	of	xenotransplantation	presents	a	number	of	biological	
challenges,	which	 include	the	risk	of	disease	transmission	 (e.g. pri-
ons	and	retroviruses),	an	immune	response	of	the	host	tissue	after	
implantation	(Schroeder	&	Mosheiff,	2011),	 lack	of	viable	cells	and	
reduced	osteoinductive	properties	due	to	manufacturing	processes	
(Zimmermann	&	Moghaddam,	2011).	Bovine	xenografts	play	a	major	
role	 and	 have	 been	 proven	 for	 cranio-	maxillofacial	 applications	
(Yamada	&	Egusa,	2018)	with	no	reports	on	Transmissible	Spongiform	
Encephalopathies	 (TSE)	 and	 Bovine	 Spongiform	 Encephalopathy	
(BSE)	risk	(Kim,	Nowzari,	&	Rich,	2013).	Results	from	a	large	retro-
spective	 analysis	with	 long-	term	observation	 time	 (Knofler,	 Barth,	
Graul,	&	Krampe,	2016),	 together	with	a	systematic	 review	of	sur-
vival	data,	indicate	that	synthetic	graft	materials	are	associated	with	
lower	dental	implant	survival	rates	than	bovine	cancellous	bone	sub-
stitutes	 (Aghaloo	&	Moy,	2007).	Nevertheless,	 in	randomized	con-
trol	clinical	trials	(Mardas,	Chadha,	&	Donos,	2010;	Mardas,	D'Aiuto,	
Mezzomo,	 Arzoumanidi,	 &	 Donos,	 2011)	 with	 a	 synthetic	 bone	
substitute	or	bovine	xenograft,	both	types	of	BGs	presented	simi-
lar	radiographic	alveolar	bone	changes	when	used	for	alveolar	ridge	
preservation.	The	same	results	were	also	obtained	when	a	BG	was	
placed	adjacent	to	a	dental	implant	(Patel,	Mardas,	&	Donos,	2013).	
Systematic	reviews	have	reported	a	reduction	in	superiorly	weighted	
mean	defects	when	used	for	lateral	bone	augmentation	around	den-
tal	implants,	although	no	randomized	controlled	trials	(RCT)	to	date	
have	compared	different	bone	replacement	grafts,	and	the	number	
of	reported	cases	that	reacted	to	xenografts	 is	significantly	higher	
F IGURE  1 Graphical	presentation	of	number	of	publications	
found	on	Web	of	Science®	after	using	the	search	terms	“bone	
graft	substitute”,	“bone	scaffold”	and	“bone	graft”	for	the	period	of	
2007–2017
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than	the	rest	of	the	biomaterials	(Sanz-	Sanchez,	Ortiz-	Vigon,	Sanz-	
Martin,	Figuero,	&	Sanz,	2015).
2.5 | Natural biomaterials
The	use	of	natural	polymers	for	bone	replacement	can	be	elucidated	
due	to	their	similarity	to	the	native	extracellular	matrix	(ECM)	and	ac-
cording	to	their	chemical	composition.	These	polymers	can	be	divided	
into	three	classes	as	follows:	(a)	proteins	(collagen,	gelatine,	fibrinogen,	
elastin);	 (b)	polysaccharides	 (glycosaminoglycans,	cellulose,	amylose);	
and	 (c)	polynucleotides	 (DNA,	RNA)	 (Corbella	et	al.,	2016;	Ceccarelli	
et	al.,	2017;	Ghassemi	et	al.,	2018).	Their	resemblance	to	native	ECMs	
results	in	high	osteoinductive	properties.	Several	strategies	have	been	
proposed	for	fabricating	a	natural	polymeric	BG:	they	can	be	derived	by	
cells,	which	are	inducted	to	produce	an	ECM,	or	directly	obtained	from	
decellularized	bone	tissue	(Pei,	Li,	Shoukry,	&	Zhang,	2011).	Autologous	
ECM-	based	bone	substitutes	are	highly	biocompatible	and	display	very	
little	risk	of	host	immune	reactions;	however,	the	need	for	an	additional	
surgery	to	sample	grafts,	with	consequent	loco-	regional	morbidity	and	
limited	availability	of	tissue,	has	not	been	a	negligible	limitation	to	this	
approach,	 similarly	 to	 autologous	 substitutes.	 Allografts	 and	 xeno-
grafts,	in	contrast,	show	no	concerns	about	biomaterial	availability	and	
have	high	osteoinductive	and	osteoblast	stimulation	properties;	how-
ever,	possible	host	immune	reactions	and	risk	of	disease	transmission	
are	still	concerns,	particularly	for	allograft-	derived	ECM-	based	grafts.	
Natural	BG	polymers	have	been	demonstrated	to	provide	mesenchy-
mal	 stem	 cell	 differentiation	 to	 the	 osteoblast	 (Wang,	 Kim,	 Blasioli,	
Kim,	&	Kaplan,	2005;	Chung	&	Burdick,	2008).	However,	mechanical	
properties	are	quite	poor	and	biodegradability	 is	 less	controllable	 in	
naturally	derived	biomaterials	compared	to	synthetic	polymers	(Mano	
et	al.,	2007;	Hannink	&	Arts,	2011).
2.6 | Synthetic materials
2.6.1 | Synthetic polymers
Synthetic	polymers	have	demonstrated	the	promising	potential	to	be	
biomaterials	for	bone	tissue	engineering	due	to	their	controllable	and	
tuneable	biomechanical	and	biodegradability	properties.	Moreover,	
they	provide	better	controllability	in	terms	of	porosity,	physiochemi-
cal	 structure	and	 immunologic	adverse	effects	when	compared	 to	
other	 types	 of	 BG	 substitutes	 (Fuchs,	 Nasseri,	 &	 Vacanti,	 2001;	
Kretlow	&	Mikos,	 2007).	 The	most	 studied	 synthetic	 polymers	 in	
bone	tissue	regeneration	are	aliphatic	polyesters	like	poly(lactic	acid)	
(PLA),	 poly(ε-	caprolactone)	 and	poly(glycolic	 acid),	 as	well	 as	 their	
copolymers	 and	 derivatives.	 These	 polymers	 are	 degraded	 by	 hy-
drolysis	in	vivo	and	have	the	advantage	of	being	easily	tailored	in	dif-
ferent	shapes,	according	to	the	mechanical	demands	in	the	particular	
bone	 treated	 (Yan	 et	al.,	 2011;	Ali	 Akbari	Ghavimi,	 Ebrahimzadeh,	
Solati-	Hashjin,	&	Abu	Osman,	2015;	Pilipchuk	et	al.,	2015).	However,	
synthetic	 polymers	 still	 show	 some	 concerns	 about	 osteoconduc-
tivity,	 absorption	 timing	 and	 local	 pH	 alterations.	 Additionally,	 all	
polymers’	surfaces	have	the	disadvantage	of	proving	inferior	cell	at-
tachment	properties.	Other	synthetic	polymers	include	poly(methyl	
methacrylate),	poly	hydroxyl	butyrate,	polyethylene,	polypropylene	
and	 polyurethane.	 Some	 polymers,	 such	 as	 poly(propylene	 fuma-
rate),	have	demonstrated	great	resistance	to	compressive	stress	and	
a	controlled	biodegradability;	however,	their	degradation	has	led	to	
the	release	of	acid	compounds	that	could	constitute	an	adverse	issue	
on	the	native	bone	(Hedberg	et	al.,	2005).
2.6.2 | Synthetic bioceramics
Synthetic	bioceramics	can	be	classified	into	several	groups	accord-
ing	to	their	silicate	content	(Figure	3)	(Müller,	2015;	Bengisu,	2016)	
because	silicate	seems	to	play	a	vital	 role	 in	bone	tissue	engineer-
ing	(Oliveira,	Malafaya,	&	Reis,	2003;	Gaharwar	et	al.,	2013;	Xavier	
et	al.,	 2015).	 Calcium	 sulphate,	 calcium	phosphate	 (CaP)	 ceramics,	
bioactive	glass	and	combinations	thereof	are	the	most	common	syn-
thetic	bone	substitutes	available	at	present	(Yang,	Lin,	Zhang,	&	Gou,	
2013).	They	are	of	special	interest	as	these	BGs	have	compositional	
similarities	to	natural	bone	(Finkemeier,	2002b).
CaP	has	received	little	or	no	attention	for	bone-	related	applica-
tions	because	of	its	biocompatibility,	biodegradability	and	similarity	
in	structure	to	the	inorganic	composition	of	bone	minerals	(Bose	&	
Tarafder,	2012).	When	compared	to	metals	and	polymers,	synthetic	
bioceramics	 are	 superior	 for	 bone	 repairs	 due	 to	 their	 improved	
biocompatibility,	bioactivity	and	strength	(Baino,	Novajra,	&	Vitale-	
Brovarone,	2015;	Hing,	2005).	The	use	of	CaP	is	motivated	by	the	fact	
that	the	primary	inorganic	component	of	bone	is	calcium	hydroxyap-
atite,	a	subset	of	the	CaP	group	(Elliott,	2002).	In	contrast,	mechani-
cal	properties	are	major	disadvantages	of	synthetic	bioceramics	and	
limit	their	use	 in	 load-	bearing	applications	 (Huang,	Wang,	&	Wang,	
2014;	 Park,	 2008).	 Improvement	 of	 the	 manufacturing	 processes,	
which	eliminate	structural	flaws	(Tiainen,	Wiedmer,	&	Haugen,	2013)	
or	improve	microstructural	features	(Georgiou	&	Knowles,	2001;	De	
Aza,	Chevalier,	 Fantozzi,	 Schehl,	&	Torrecillas,	 2002)	 or	 composite	
structures	 (Miao,	 Tan,	 Li,	 Xiao,	 &	 Crawford,	 2008;	 Novak,	 Druce,	
Chen,	&	Boccaccini,	2009),	 is	alternatives	in	improving	the	intrinsic	
strength	 of	 synthetic	 bioceramics.	 The	most	 investigated	 CaP	 BG	
substitutes	are	hydroxyapatite,	beta-	tricalcium	phosphate	and	their	
F IGURE  2 Flowchart	of	the	record-	selection	process
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combination,	 also	 called	 biphasic	 calcium	 phosphate	 (Dorati	 et	al.,	
2017).	Synthetic	bioceramics	have	demonstrated	the	ability	to	par-
tially	integrate	into	natural	bone	tissue	and	stimulate	osteoblast	dif-
ferentiation,	osteoblast	growth	and	 inorganic	matrix	deposition.	 In	
addition	to	CaP's	composition,	structure	and	crystallinity	also	play	a	
role	in	how	osteoblasts	proliferate	and	differentiate	when	in	contact	
with	CaP	and	can	be	partially	tuned	as	needed	during	the	fabrication	
process	 (Laurencin,	Khan,	&	Veronick,	2014).	However,	 the	clinical	
applications	 of	 CaP	 bone	 substitutes	 are	 limited	 by	 their	 fragility,	
as	well	as	 their	unpredictable	absorption	rate	while	not	being	able	
to	maintain	their	defect	volume,	which	makes	the	CaP	have	overall	
less	favourable	clinical	outcomes.	Thus,	new	bone	tissue	formed	in	a	
CaP	BG	mostly	cannot	sustain	mechanical	loading	and	natural	bone,	
and	such	biomaterials	are	mainly	used	for	particulates	and	applied	to	
bone-	void	fillings	in	low-	load-	bearing	applications.	More	recently,	it	
has	been	shown	that	doping	CaP	BG	with	various	compounds	could	
improve	mechanical	resistance,	biocompatibility	and	absorption	rate.	
For	 instance,	 Fielding,	 Bandyopadhyay,	 and	 Bose	 (2012)	 demon-
strated	that	the	addiction	of	silicon	and	zinc	oxides	to	beta-	tricalcium	
phosphate	increased	compressive	strength	to	2.5-	fold	and	cell	viabil-
ity	to	92%;	however,	clinical	evidence	is	still	lacking.	Bioglass®	such	
as	45S5	experiences	the	same	issue	with	lower	mechanical	strength	
and	 locally	 increased	 in	 pH	 values,	 despite	 excellent	 material-	
bone	 interactions	 (Chen,	 Thompson,	 &	 Boccaccini,	 2006;	 Jones,	
Ehrenfried,	 &	Hench,	 2006;	Wu,	 Luo,	 Cuniberti,	 Xiao,	 &	Gelinsky,	
2011).	 Other	 ceramics,	 like	 titanium	 dioxide,	 have	 demonstrated	
biocompatibility	 and	 osteoconductive	 properties	 in	 vitro	 (Verket	
et	al.,	2012;	Sabetrasekh	et	al.,	2010;	Gomez-	Florit	et	al.,	2012)	and	
in	vivo	 (Tiainen,	Wohlfahrt,	Verket,	 Lyngstadaas,	&	Haugen,	2012;	
Haugen	et	al.,	2013).	Although	in	vivo	animal	model	data	are	promis-
ing,	clinical	data	are	still	lacking.	Furthermore,	new	approaches	to	the	
problem	of	brittleness	of	ceramic	BG	substitutes	include	composite	
materials	 in	which	CaP	 is	mixed	with	 organic	 polymers	 (Laurencin	
et	al.,	2014).	Composite	BGs	also	demonstrated	a	promising	role	 in	
drug	delivery,	thanks	to	their	porosity	and	cell	adhesion	ability	(Alves	
Cardoso,	Jansen,	&	Leeuwenburgh,	2012).
2.6.3 | Combination of synthetic and xenograft 
bone graft substitutes (xenohybrid)
It	 is	 a	 generally	 accepted	 paradigm	 that	 bone	 substitutes	 should	
resemble	naturally	 occurring	human	 cancellous	bone	 as	 closely	 as	
Bone graft (BG) Advantages Disadvantages
Autologous •	 high	osteoconductivity
•	 highest	degree	of	biological	
safety
•	 no	risk	of	immune	reaction
Need	of	an	additional	surgery
Xenografts •	 architecture	and	geometric	
structure	resemble	bone
•	 Well	documented
•	 predictable	clinical	outcome
•	 slow	bio-absorbability	
preserves	augmented	bone	
volume
•	 possible	disease	transmission	
and	potential	unwanted	
immune	reactions
•	 lacks	viable	cells	and	
biological	components
•	 resorption	rate	is	highly	
variable
•	 reduced	future	availability	
due	European	regulatory	
changes	?
Natural	biomaterials Similarity	to	native	extracellular	
matrix
Mechanical	properties	poor	
-	biodegradability	less	
controllable
Synthetic	polymers •	 tuneable	physicochemical	
properties
•	 tuneable	degradability
•	 low	cell	attachment
•	 timing	of	absorption	
(alteration	of	mechanical	
properties)
•	 release	of	acidic	degradation	
products
Synthetic	
bioceramics
•	 high	biocompatibility
•	 osteoinductive	properties
•	 chemical	similarity	with	bone
•	 stimulation	of	osteoblast	
growth
•	 high	brittleness
•	 low	ductility
•	 not	predictable	absorption
Composite	
xenohybrid	
substitutes
•	 high	similarity	with	human	
cancellous	bone
•	 higher	bioactivity
•	 tailored	degradation	rates
•	 incorporation	of	active	
biomolecules
•	 cleaning	and	sterilization	
process	partially	alters	
biological	performances
•	 limited	clinical	data
TABLE  1 Summary	of	main	advantages	
and	disadvantages	of	BG
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possible.	Therefore,	a	very	commonly	used	source	of	bone	matrices	
is	 animal-	derived	 bones;	 bovine	 xenografts,	 distantly	 followed	 by	
equine	and	porcine,	are	commonly	used	in	clinical	practice.	Bovine-	
derived	cancellous	BGs	are	acknowledged	as	the	closest	xenograft	
to	human	bone	to	be	regenerated,	second	only	to	autografts	(Datta,	
Gheduzzi,	&	Miles,	2006;	Athanasiou	et	al.,	2010),	and	are	consid-
ered	safe	products	that	can	be	used	daily	in	clinical	practices	where	
bone	 regeneration	 is	needed	 in	 reconstructive	 surgeries	 (Capanna	
et	al.,	2014;	Knofler	et	al.,	2016).	However,	necessary	cleaning	and	
sterilization	processes	for	starting,	raw	materials	of	animal	origin	re-
sult	 in	 the	 decay	 of	 both	mechanical	 and	 biological	 performances	
(Vishwakarma,	Sharpe,	Shi,	&	Ramalingam,	2014).	 Indeed,	similarly	
to	 what	 has	 been	 seen	 for	 synthetic	 biomaterials,	 the	 applica-
tion	of	combining	synthetic	materials	with	xenografts	 is	becoming	
an	 interesting	 trend,	 not	 only	 in	 research	 (Ceccarelli	 et	al.,	 2017)	
but	 also	 in	 industrial	 and	 clinical	 practices	 (Pertici,	 Rossi,	 Casalini,	
&	 Perale,	 2014;	 Stacchi	 et	al.,	 2018).	 Some	 studies	 claim	 that	 this	
combination—this	new	generation	of	BG—provides	enhanced	clini-
cal	performance	(Pertici	et	al.,	2014;	Rossi,	Santoro,	&	Perale,	2015;	
D'Alessandro	 et	al.,	 2017;	 Stacchi	 et	al.,	 2018),	 even	 though	 clear	
evidence	of	osteoinductivity	does	not	yet	exist	(Roato	et	al.,	2018).	
Adding	resorbable	polymeric	components	can	also	be	used	to	local,	
carry	active	molecules,	or	drugs	to	be	delivered	locally,	to	increase	
cell	colonization,	promote	osteoinduction	and,	 finally,	promote	os-
teogenesis	(D'Alessandro	et	al.,	2017;	Roato	et	al.,	2018).
3  | DISCUSSION
There	is	an	increasing	awareness	of	allografts	and	bone	substitutes	in	
general,	but	European	dentists	still	prefer	xenografts	as	substitutes	
due	to	their	clinical	predictability.	More	scientific	literature	and	com-
parative	studies	need	to	be	provided	to	convince	dentists	that	new	
BGs	can	provide	more	advantages	than	current	xenografts	(Larsson	
&	Hannink,	2011).	Given	that	the	supply	of	allografts	may	be	limited	
in	the	future,	dentists	should	consider	substituting	such	grafts	with	
more	synthetics	ones	(Bostrom	&	Seigerman,	2005;	Bohner,	2010).	
Synthetic	and	composite	BGs	are	progressively	being	incorporated	
into	cranio-	maxillofacial	treatments	as	dentists	are	becoming	aware	
of	their	benefits.
In	 the	cranio-	maxillofacial	 area,	 few	competitors	 lead	 the	mar-
ket;	 indeed,	 the	 European	 BG	 market	 is	 dominated	 by	 one	 com-
pany,	a	 large	manufacturer	that	holds	more	than	half	of	all	market	
shares	(MarketReport,	2017).	Manufacturers	are	required	to	assess	
their	products	through	extensive	clinical	trials	to	demonstrate	their	
clinical	 efficacy	 and	 reduce	 potential	 risks	 with	 respect	 to	 gold	
standards.	 The	 results	 emerging	 from	 clinical	 trials	 are	 an	 import-
ant	factor	that	surgeons	should	use	when	they	select	products.	For	
example,	 a	 porous	 beta-	tricalcium	 phosphate	 has	 gained	 positive	
acceptance	 since	 its	 introduction	 because	 of	 the	 successful	 clini-
cal	 trial	outcomes	surrounding	 it	 (Damron,	2007;	Sinha,	Menon,	&	
Chakranarayan,	 2009;	 Damron	 et	al.,	 2013).	 However,	 although	
allografts	and	Demineralized	bone	matrix	products	were	used	suc-
cessfully	 for	 several	 years,	 their	high	costs	and	 lack	of	 substantial	
clinical	data	hindered	revenue	growth.	The	recent	development	of	
novel	BG	substitutes	is	associated	with	advanced	production	meth-
ods	such	as	3D	printing	 (Inzana	et	al.,	2014).	The	mass	production	
of	this	material	can	therefore	be	difficult	and	costly.	Because	these	
materials	generate	 lower	revenues	 in	the	market,	 introducing	such	
novel	BGs	to	the	market	can	be	challenging.	Biomaterial	scientists	
working	 in	 the	 academic	 field	 often	do	not	 consider	 scale-	up	 and	
certification-	related	 problems	when	developing	 a	 new	biomaterial	
for	bone	tissue	engineering	purposes.
Synthetic	 materials	 have	 the	 lowest	 osteoinductivity	 of	 any	
of	 the	major	BG	types	and	are	not	as	widely	accepted	as	 the	al-
lograft	materials	 (Garcia-	Gareta,	Coathup,	&	Blunn,	2015;	Miron	
et	al.,	2016).	Despite	the	obvious	benefits	of	a	synthetic	BG,	they	
still	 lack	 significant	market	penetration	due	 to	 the	 lack	of	docu-
mented	 clinical	 studies	 supporting	 their	 effectiveness.	 This	 lack	
of	acceptance	has	translated	into	a	preference	for	xenografts	over	
synthetic	materials	among	the	majority	in	the	cranio-	maxillofacial	
field.	Although	this	preference	hinders	synthetic	BGs	from	gaining	
more	market	shares,	a	recent	medical	device	regulation	may	pro-
vide	a	new	market	opportunity	for	synthetic	BGs	(MarketReport,	
2018,	MDR,	2017).
As	 Yamada	 &	 Egusa,	 (2018)	 concluded	 in	 a	 recent	 review:	
“Autogenous	bone	 is	 still	 the	gold	standard	and	accelerates	 ini-
tial	 bone	 formation	 to	 a	 greater	 extent	 than	 bone	 substitutes.	
However,	 autogenous	 bone	 is	 only	 effective	 under	 favourable	
recipient	 conditions	 and	 thus	 requires	 supplementation	 with	
bone	 substitutes	 in	 bone	 augmentation	 under	 severe	 recipient	
conditions.	The	biocompatibility	of	current	bone	substitute	ma-
terials	should	be	 improved”.	With	respect	to	this	statement,	we	
agree	that	current	bone	replacement	graft	materials	need	to	be	
“smarter”	and	elicit	a	more	desirable	host	response,	not	only	for	
regular	patients	but	also	for	more	challenging	cases.	In	this	field,	
several	 drug	 therapies	 have	 been	 studied	 for	 their	 potential	 in	
enhancing	bone–tissue	healing.	Historically,	growth	factors	have	
attracted	considerable	attention	because	 they	are	 fundamental	
for	 bone	 regeneration.	 Bone	morphogenetic	 protein-	2	 (BMP-	2)	
F I G U R E  3 Classification of bioceramic 
bone grafts divided into silicate and non-
silicate ceramics according to their main 
composition (adapted from Müller 2016)
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and	bone	morphogenetic	protein-	7	(BMP-	7)	are	the	most	exten-
sively	investigated	growth	factors	due	to	their	ability	to	promote	
differentiation	 in	mesenchymal	stem	cells	 to	osteoblasts	 (Chen,	
Deng,	&	Li,	2012;	Grayson	et	al.,	 2015;	Scarfi,	2016).	However,	
the	 administration	 of	 recombinant	 BMPs	 have	 been	 used	 in	
concentrations	 overshooting	 physiologically	 occurring	 concen-
trations	 in	 orthopaedic	 settings	 and	 has	 raised	 concerns	 about	
documented	 side	 effects	 (Boraiah,	 Paul,	 Hawkes,	 Wickham,	 &	
Lorich,	 2009;	 Emara,	Diab,	&	Emara,	 2015;	 Epstein,	 2013).	 The	
parathyroid	hormone,	which	has	already	been	approved	for	 the	
treatment	of	osteoporosis,	could	also	be	a	valid	therapy	for	bone	
healing	 (Vahle	et	al.,	2002;	Pilitsis,	Lucas,	&	Rengachary,	2002).	
Bisphosphonates	have	been	demonstrated	as	optimal	drugs	 for	
targeting	bones	and	are	among	the	most	studied	molecules	in	the	
field.	Several	studies	proved	their	efficacy	by	carrying	antibiotics	
or	chemotherapy	agents	to	the	bone	and	accredited	their	affinity	
to	 hydroxyapatite	 (Stapleton	 et	al.,	 2017).	Antibodies	 have	 also	
been	 suggested	 as	 a	 model	 to	 target	 the	 bone	 in	 diverse	 con-
ditions.	 In	addition,	novel	approaches	 including	small	molecules	
and	 peptides	 (and	 synthetic	 derivatives	 thereof),	 like	 steroids,	
prostaglandin	 agonists,	 collagen,	 amelogenins	 and	 Wnt/beta-	
catenin	agonists	have	been	explored,	as	 they	are	 relatively	sta-
ble,	affordable	and	display	little	immunogenicity	(Lo,	Ashe,	Kan,	
&	Laurencin,	2012;	Hoffman	&	Benoit,	2015;	Benoit,	Nuttelman,	
Collins,	&	Anseth,	2006).	Synthetic	derivatives	of	the	aforemen-
tioned	molecules	have	shown	a	positive	influence	in	in	vitro	and	
in	vivo	studies	(Rubert	et	al.,	2013;	Villa	et	al.,	2015).	An	alterna-
tive	strategy	 is	 represented	by	the	delivery	of	nucleotides	such	
as	siRNA	and	miRNA,	which	can	be	used	to	genetically	rearrange	
cells	 acting	 at	 the	 site	 of	 healing	 and	 thus	 improve	 the	 regen-
eration	 of	 bone	 tissue	 (Murata	 et	al.,	 2014;	Wang,	Malcolm,	 &	
Benoit,	2017).	 It	should	be	noted	that	all	these	strategies	result	
in	products	that	will	be	considered	as	pharmaceutical	entities	and	
not	 medical	 devices,	 with	 additional	 regulatory	 consequences	
and	higher	costs.
4  | CONCLUSIONS
Depending	on	the	clinical	problem,	different	types	of	substitutes	or	
combinations	thereof	are	necessary.	Even	though	the	ideal	proper-
ties	of	BG	have	already	been	defined	in	the	literature	three	decades	
ago,	 the	market	 still	 has	 no	 available	 biomaterials	 that	meet	 all	 of	
these	properties.	The	evolution	of	new-	generation	BGs	continues	to	
evolve	with	novel	biomaterials	and	processing	methods	such	as	ad-
ditive	manufacturing.	Current	changes	in	EU	regulations	of	medical	
devices	may	increase	the	use	of	synthetic	materials.
The	 ideal	 BG	 in	 the	 future	 will	 likely	 contain	 a	 combination	
of	 biomaterials	 with	 varying	 features	 that	 can	 control	 mechani-
cal	 properties,	 pore	 morphology,	 interconnective	 pores,	 surface	
structure,	release	of	active	bone-	promoting	biomolecules	and	con-
trolled	biodegradability,	which	ensures	resorption	during	the	tissue-	
remodelling	process	while	maintaining	the	defect	volume	for	bone	
ingrowth.	These	features	will	improve	osteoinduction	compared	to	
today's	BG	material.
Because	few	comparative	studies	have	reported	on	in	vivo	and	
clinically	different	BGs,	the	obvious	benefits	of	newer	BGs	are	not	
documented	well	enough.	For	 future	BGs	 to	gain	market	penetra-
tion,	there	is	a	desire	for	further	comparative	studies	that	use	stan-
dardized	 and	 validated	 pre-	clinical	models,	 both	 to	 screen	models	
in	small	animals	but	also	provide	validation	to	large-	animal	models.
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